These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

568 related items for PubMed ID: 26834096

  • 1. ¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer.
    Groheux D, Cochet A, Humbert O, Alberini JL, Hindié E, Mankoff D.
    J Nucl Med; 2016 Feb; 57 Suppl 1():17S-26S. PubMed ID: 26834096
    [Abstract] [Full Text] [Related]

  • 2. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G.
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [Abstract] [Full Text] [Related]

  • 3. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
    Groheux D, Hindié E, Marty M, Espié M, Rubello D, Vercellino L, Bousquet G, Ohnona J, Toubert ME, Merlet P, Misset JL.
    Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
    [Abstract] [Full Text] [Related]

  • 4. Whole-body 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) for staging locally advanced breast cancer: A prospective study from a tertiary cancer centre in south India.
    Gajjala SR, Hulikal N, Kadiyala S, Kottu R, Kalawat T.
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [Abstract] [Full Text] [Related]

  • 5. Performance of FDG PET/CT in the clinical management of breast cancer.
    Groheux D, Espié M, Giacchetti S, Hindié E.
    Radiology; 2013 Feb; 266(2):388-405. PubMed ID: 23220901
    [Abstract] [Full Text] [Related]

  • 6. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
    Hogan MP, Goldman DA, Dashevsky B, Riedl CC, Gönen M, Osborne JR, Jochelson M, Hudis C, Morrow M, Ulaner GA.
    J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
    [Abstract] [Full Text] [Related]

  • 7. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience.
    Sharma P, Jain TK, Singh H, Suman SK, Faizi NA, Kumar R, Bal C, Malhotra A, Kumar R.
    Nucl Med Commun; 2013 Mar; 34(3):211-9. PubMed ID: 23353886
    [Abstract] [Full Text] [Related]

  • 8. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S.
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [Abstract] [Full Text] [Related]

  • 9. 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging.
    Groheux D, Giacchetti S, Delord M, Hindié E, Vercellino L, Cuvier C, Toubert ME, Merlet P, Hennequin C, Espié M.
    J Nucl Med; 2013 Jan; 54(1):5-11. PubMed ID: 23213197
    [Abstract] [Full Text] [Related]

  • 10. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
    Ng SP, David S, Alamgeer M, Ganju V.
    Int J Radiat Oncol Biol Phys; 2015 Sep 01; 93(1):111-7. PubMed ID: 26279029
    [Abstract] [Full Text] [Related]

  • 11. FDG PET, PET/CT, and breast cancer imaging.
    Rosen EL, Eubank WB, Mankoff DA.
    Radiographics; 2007 Oct 01; 27 Suppl 1():S215-29. PubMed ID: 18180228
    [Abstract] [Full Text] [Related]

  • 12. The role of (18)F-FDG PET/CT in initial staging of patients with locally advanced breast carcinoma with an emphasis on M staging.
    Mittal BR, Manohar K, Kashyap R, Bhattacharya A, Singh B, Singh G.
    Hell J Nucl Med; 2011 Oct 01; 14(2):135-9. PubMed ID: 21761015
    [Abstract] [Full Text] [Related]

  • 13. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Groheux D, Giacchetti S, Delord M, de Roquancourt A, Merlet P, Hamy AS, Espié M, Hindié E.
    Eur J Nucl Med Mol Imaging; 2015 Mar 01; 42(3):377-85. PubMed ID: 25432784
    [Abstract] [Full Text] [Related]

  • 14. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
    Alberini JL, Lerebours F, Wartski M, Fourme E, Le Stanc E, Gontier E, Madar O, Cherel P, Pecking AP.
    Cancer; 2009 Nov 01; 115(21):5038-47. PubMed ID: 19645022
    [Abstract] [Full Text] [Related]

  • 15. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G, Altini C, Notaristefano A, Merenda N, Rubini D, Ianora AA, Asabella AN.
    Rev Esp Med Nucl Imagen Mol; 2014 Nov 01; 33(1):22-7. PubMed ID: 23948509
    [Abstract] [Full Text] [Related]

  • 16. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
    García Vicente AM, Soriano Castrejón A, Cruz Mora MÁ, Ortega Ruiperez C, Espinosa Aunión R, León Martín A, González Ageitos A, Van Gómez López O.
    Rev Esp Med Nucl Imagen Mol; 2014 Nov 01; 33(1):1-5. PubMed ID: 23707190
    [Abstract] [Full Text] [Related]

  • 17. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V, Delrue L, Kelles A, Van Damme N, Van Huysse J, Berrevoet F, De Vos M, Duyck P, Peeters M.
    Acta Gastroenterol Belg; 2007 Nov 01; 70(4):331-8. PubMed ID: 18330088
    [Abstract] [Full Text] [Related]

  • 18. The utility of 18 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification.
    Cochet A, David S, Moodie K, Drummond E, Dutu G, MacManus M, Chua B, Hicks RJ.
    Cancer Imaging; 2014 Apr 22; 14(1):13. PubMed ID: 25608599
    [Abstract] [Full Text] [Related]

  • 19. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT, Hu C, Chiu YL, Peng NJ, Liu RS.
    PLoS One; 2014 Apr 22; 9(12):e115127. PubMed ID: 25517451
    [Abstract] [Full Text] [Related]

  • 20. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS, Shahin MA.
    Nucl Med Commun; 2012 Mar 22; 33(3):313-21. PubMed ID: 22237387
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.